H.I.G. BioVentures

Download Report

Transcript H.I.G. BioVentures

H.I.G. BioVentures

July 29, 2011

H.I.G. Capital – Corporate Overview

       H.I.G. is one of the leading private equity firms in the small-cap segment of the market Founded in 1993; over $9 Billion under management More than 200 investment professionals Offices: • North America: Miami, Atlanta, Boston, San Francisco, New York, Maryland • Europe: London, Paris, Hamburg H.I.G. Funds: • Venture/Growth Investments: H.I.G. BioVentures; H.I.G. Growth Partners • Buyout Investments: U.S. LBO, Europe LBO • Distressed Investments: Bayside Capital (debt) • Public Equities: Brightpoint Capital “Institutionalized” management structure/processes with strong financial staff/controls, legal/compliance, IT support, and risk management procedures in place Differentiated, value-added strategy has resulted in superior track record


H.I.G. BioVentures – Background

 Established dedicated life science focus in 2004 : • Approximately $350 Million in capital under management • $150 Million committed to existing portfolio companies • Currently investing out of H.I.G. BioVentures II • Experienced team focused exclusively on life science investing  Sectors: biopharmaceuticals, medical devices, diagnostics  H.I.G. BioVentures is the lead or co-lead investor in all investments • Active board representation in all companies


H.I.G. BioVentures – Team

 Four senior investment professionals with collectively more than 30 years of venture capital investing experience  The H.I.G. BioVentures team has complementary backgrounds covering • Research and intellectual property • • Product and process development Business development • • • Operations Finance Sales and marketing  The H.I.G. BioVentures team also has a deep network of advisors, co investors, corporate leaders, and technical consultants to leverage during due diligence and on behalf of portfolio companies


H.I.G. BioVentures – Industry Leadership

 The H.I.G. BioVentures team is active with numerous academic and non-profit organizations • Boards of regional venture capital organizations: o Mid-Atlantic Venture Association (MAVA), FL Bio, GA Bio • Board and committee participation at national and regional conferences: o Bio-Investor Forum, Mid-Atlantic Bio, Southeast Bio Investor Forum, FL Venture Forum, Midwest Healthcare Investor Network • Board/advisory member for universities and entrepreneurial organizations : o Johns Hopkins Alliance, Maryland Technology Enterprise Institute, North Texas Enterprise Corporation, Texas Bioscience Council, Coulter Foundation (Emory, Ga. Tech), Sid Martin Biotechnology Incubator , Univ. Miami, Univ. Florida, Univ. Delaware Research Foundation, Virginia CIT Gap Fund Investment Board (affiliated with all Virginia Universities), Enterprise Florida • Not-for-profit boards : o Adventist Healthcare • Speaker/panelist : o Multiple national and regional conferences including BIO 2011


H.I.G. BioVentures – Aaron Davidson

Executive management at Eli Lilly and Company • Business development • Sales and marketing • Finance • General management  Venture capital experience at Ventures West • Leading Canadian healthcare investor  Operating history at Eli Lilly and Company and venture-backed SYN-X Pharma  Broad network in the pharmaceutical and biotechnology industry as well within the venture capital community.

  M.B.A., Harvard Business School B.Comm., McGill University

[email protected]

(305) 379-2322 10

H.I.G. BioVentures – Bruce Robertson

 Operating experience in both business development and R&D • IGEN (acquired by Roche) • W.R. Grace  Venture capital experience at Toucan Capital and GIV Venture Partners  Extensive relationships in the Mid Atlantic’s financial, entrepreneurial and scientific/academic community  Well-connected within broad venture capital community    M.B.A., Harvard Business School Ph.D., University of Delaware (Biomedical Engineering) B.S.E., University of Pennsylvania

11 [email protected]

(305) 379-2322

H.I.G. BioVentures – Michael Wasserman

 Operating experience in entrepreneurial/venture backed biotechnology • Founder and VP, Business Development at CELLutions Biosystems (acq. by Cedarlane Labs)  Background in early-stage technology transfer and development as a Principal with Innovations Foundation  Clinical drug development and regulatory expertise based on tenure at Advanced Therapeutics  Extensive network and deal flow resources in multiple geographies – Southeast, Midwest, Texas, Ohio, etc.

  Ph.D., University of Toronto (Pharmacology) B.S., McGill University

12 [email protected]

(305) 379-2322

H.I.G. BioVentures – Michael Gutch

 Venture Capital experience at Lilly Ventures, Eli Lilly and Company  Member of the Corporate Finance & Investment Banking group at Eli Lilly and Company  Post-doctoral research experience at Cold Spring Harbor Labs and UCSF  Strong associations in the pharmaceutical and entrepreneurial communities and networked throughout the Midwest and Northwest    M.B.A., Indiana University Ph.D., State University of New York (Molecular & Cellular Pathology) B.S., Alfred University

[email protected]

(305) 379-2322 13

H.I.G. BioVentures – Investment Strategy

Investment Strategy Areas of Unmet Medical Need Efficient Clinical Development Validation & Differentiation Broad Source of Deal Flow • Large, attractive markets • Significant unmet medical needs • Chronic or acute care high value per patient disease indications • Clear and meaningful clinical end-points • Short clinical development timelines to demonstrate proof of-concept in appropriate patient groups • Scientific and clinical validation well established • Differentiation from current standard of care • Regulatory precedent established • Extensive networks outside of CA and MA resulting in proprietary deal flow • Approximately 80% of investments in “secondary geographies”


H.I.G. BioVentures – Partnering with Industry

  H.I.G. BioVentures values its long-term relationships with the pharma and medical device industries H.I.G. BioVentures has: • Co-invested with corporate venture capital groups such as MedImmune Ventures, SROne, Novo A/S • Strong relationships with most pharmaceutical and med-tech corporate venture capital and business development groups • Ongoing discussions with CVC and BD groups on existing portfolio companies and new deal opportunities  H.I.G. BioVentures portfolio companies have recently completed transactions with:


H.I.G. BioVentures – Summary

 Dedicated to investing in high potential life sciences companies  Team of experienced investment professionals with deep domain knowledge  Proprietary deal flow developed through a broad relationship network  Ability to leverage the more than 200 investment professionals across the H.I.G. Capital platform  Building business relationships with pharmaceutical, biotechnology, and medical device companies